Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionClinical Trial Published on 2022-11-012023-06-13 Journal: Journal of hepatology [Category] B형 간염, [키워드] ABI-H0731 Chronic hepatitis B virus core inhibitor entecavir nucleos(t)ide reverse transcriptase inhibitor Phase 2 Treatment-naïve. Vebicorvir [DOI] 10.1016/j.jhep.2022.05.027 PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trialArticle Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] 진단, [키워드] Administered adverse event age binding antibody clinical trial Comorbidities Comorbidity COVID-19 infection demonstrated dose double-blind elicited General population High dose High-dose immune response immunization immunogenicity immunosenescence Mild mortality rates MVC-COV1901 vaccine negative correlation Neutralizing Older older adult Older adults participant Phase 2 protein subunit vaccine Randomized regimen Registered robust Safety SARS-CoV-2. stratified subject Trial Vaccine [DOI] 10.1016/j.ijid.2022.08.021 PMC 바로가기
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19Article Published on 2022-10-192022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% CI Administered administration Adverse affected analysed antiviral therapy Antiviral treatment ARMS baseline changed Combination combination therapy concentrations conducted coronavirus 2 COVID-19 COVID-19 pandemic Day Dose escalation doses double-blind double-blind trial drug level effective Efficacy evaluate the effect event Favipiravir healthy Interaction Lopinavir-ritonavir measure monotherapy Odds ratio Outpatient participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial placebos plasma primary analysis Primary outcome provided randomised recruited reduced respiratory SARS-CoV-2 SARS-CoV-2 viral load significant interaction significantly study population symptom onset the mean trajectory Treatment undetectable United Kingdom Viral load virus [DOI] 10.1371/journal.pmed.1004120 PMC 바로가기
Wellbeing and coping of UK nurses, midwives and allied health professionals during COVID-19-a cross-sectional studyArticle Published on 2022-09-212022-11-16 Journal: PLoS ONE [Category] SARS, 변종, [키워드] backbone benefit Burnout Care conducted COPE coping coping strategies Coping strategy COVID-19 pandemic cross-sectional cross-sectional survey Descriptive statistics Deterioration Effect examined family Final Health healthcare Healthcare professional healthcare services inventory life mental health Multiple linear regression Nurse Nurses patients with COVID-19 phase Phase 1 Phase 2 Prevent professional Psychological Quality repeated respond scale significant effect significantly lower Strategy Stressor timepoints United Kingdom variable variant work [DOI] 10.1371/journal.pone.0274036 PMC 바로가기
Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populationsArticle Published on 2022-09-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, [키워드] Advax-CpG adverse event antibody Cellular immune response composed conducted COVID-19 COVID-19 vaccine dose double-blind fatigue geometric mean concentration humoral incidence injection site pain Mild outcome participant phase Phase 2 phase 2 trial Placebo placebo-controlled Population primary immunogenicity Protein Randomized randomized placebo-controlled trial receive Safety safety profile SARS-CoV-2 SARS-CoV-2 spike protein second dose Serious Adverse Event Seroconversion seroconversion rate seronegative seropositive SpikoGen subunit subunit protein vaccine. the placebo group vaccination Vaccine Volunteer were recorded [DOI] 10.1016/j.cmi.2022.04.004 PMC 바로가기
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial2019년 코로나바이러스 질환 입원 환자에서 사릴루맙의 효능 및 안전성: 무작위 임상 시험Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, 진단, [키워드] 95% CI 95% confidence interval adaptive adults hospitalized analysis anti-IL-6R monoclonal antibody baseline benefit clinical clinical status coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids corticosteroids) COVID-19 Critical death double-blind Efficacy Efficacy and safety evaluated hazard ratio Hospitalized hospitalized patient hospitalized patients interleukin interleukin-6 interleukin-6 receptor intravenous mechanical ventilation Meta-analysis monoclonal antibodies monoclonal antibodies. Patient patients randomized Phase 2 phase 2/3 Phase 3 Placebo placebo-controlled trial Platform trial Post hoc analyses Post hoc analysis primary analysis population Primary outcome proportion Randomized receiving Relative risk risk risk difference Safety sarilumab therapy treated Treatment Trial with COVID-19 [DOI] 10.1093/cid/ciac153 PMC 바로가기 [Article Type] Randomized Controlled Trial
A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial – implications for therapeutic immune modulationResearch article Published on 2022-08-182022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, 변종, 임상, [키워드] 1:1 Activation Adaptive immune response addition adverse event ARCADIA assigned AZD1656 Clinical improvement clinical trial Complete COVID-19 cytokine Czech Republic Day death decrease diabetes diabetic patient diabetic patients dose double-blind duration of hospitalisation Efficacy Excalibur False positive finding Full Analysis Set funding Glucokinase activator group homeostatic hospital hospital discharge hospitalised identify immune Immune cell immune modulation immune response Immunochemistry immunomodulatory effect Immunophenotyping implication indicated Innovation investigated involved less Medicine multicentre nine no difference Patient phase Phase 2 Placebo placebo-controlled placebo-controlled clinical trial primary analysis primary endpoint pro-inflammatory randomised Randomly receive recruited reduction in Registered regulatory T cells required risk Romania SARS-CoV-2 screened statistically significant difference suggested Tablet the placebo group therapeutic therapeutic effect treated Treatment treatment allocation Tregs Trial usual care with COVID-19 [DOI] 10.1016/j.eclinm.2022.101604 [Article Type] Research article
Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variantsSARS-CoV-2 변종을 차단하는 범용 약제로서의 임상 등급 ACE2Article Published on 2022-08-082022-09-11 Journal: EMBO Molecular Medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 Alpha analyzed Beta binding affinity caused clinical clinical trial COVID-19 Delta develop Efficacy epithelial cell epithelial cells Gamma human lung human lung epithelial cells independent Infection inhibit inhibited neutralized neutralizing antibody omicron Phase 2 principle proof reduced SARS-CoV-2 isolates SARS-CoV-2 variant SARS-CoV-2 variants several variant several variants soluble ACE2 strain tested therapeutic Therapeutic strategies therapeutic strategy These data Treatment Vaccine vaccine. variants variants of concern VeroE6 cell VeroE6 cells VoC [DOI] 10.15252/emmm.202115230 PMC 바로가기 [Article Type] Article
rVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbitsrVSV-ΔG-SARS-CoV-2-S 백신: NZW 토끼에서 반복되는 근육내(IM) 독성, 국소 내성, 면역원성 및 생체 분포 연구Article Published on 2022-08-012022-09-11 Journal: Archives of Toxicology [Category] COVID19(2023년), MERS, SARS, 비임상, 진단, 치료기술, [키워드] Administered animals antibody antibody levels Antibody titers Antigen assigned binding biodistribution biodistribution study body temperature body weight breath C-reactive protein change Clinical pathology Clinical signs clinical trial clinical trials correlated COVID-19 detection elicited evaluate Express followed by Gross High-dose high-dose group histopathological iliac lymph node immunogenicity inflammatory reaction injection intervals intramuscular intramuscularly Local local reactions Lymph node mesenteric lymph nodes Necrosis Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers New Nonclinical ophthalmology pathology Phase 2 platform Reactions repeated RNA Safe Safety SARS-CoV-2 SARS-CoV-2-S significant increase spleen stomatitis supported systemic the vaccine Tolerance Toxicity two group two groups Urinalysis vaccination Vaccine vaccine doses vaccine. Vector-based vaccine vesicular stomatitis vesicular stomatitis virus Viremia VSV was performed [DOI] 10.1007/s00204-022-03302-5 PMC 바로가기 [Article Type] Article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial